OA11659A - Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. - Google Patents

Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. Download PDF

Info

Publication number: OA11659A
Authority: OA; OAPI
Prior art keywords: acetyldinaline; gemcitabine; combination; dose; cancer
Prior art date: 1998-09-25

Application number

OA1200100078A

Other languages

English (en)

Inventor

William Richard Grove

Wayne Daniel Klohs

Ronald Lynn Merriman

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-25

Filing date

1999-07-08

Publication date

2004-12-08

1999-07-08 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2004-12-08 Publication of OA11659A publication Critical patent/OA11659A/en

Links

VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 title claims abstract description 105
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title claims abstract description 66
229960005277 gemcitabine Drugs 0.000 title claims abstract description 58
206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 28
229960004316 cisplatin Drugs 0.000 title claims abstract description 28
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title claims abstract description 23
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title claims abstract description 22
229960004117 capecitabine Drugs 0.000 title claims abstract description 22
201000011510 cancer Diseases 0.000 title claims abstract description 20
238000002512 chemotherapy Methods 0.000 title description 5
238000011282 treatment Methods 0.000 claims description 32
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
230000000259 anti-tumor effect Effects 0.000 claims description 7
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 3
208000009956 adenocarcinoma Diseases 0.000 claims description 2
229940046044 combinations of antineoplastic agent Drugs 0.000 claims description 2
230000001394 metastastic effect Effects 0.000 claims description 2
206010061289 metastatic neoplasm Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
230000002195 synergetic effect Effects 0.000 abstract description 9
150000003839 salts Chemical class 0.000 abstract description 2
230000000694 effects Effects 0.000 description 19
229940079593 drug Drugs 0.000 description 17
239000003814 drug Substances 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 14
230000012010 growth Effects 0.000 description 13
238000000034 method Methods 0.000 description 13
230000004044 response Effects 0.000 description 13
231100000682 maximum tolerated dose Toxicity 0.000 description 10
229960005144 gemcitabine hydrochloride Drugs 0.000 description 9
238000012360 testing method Methods 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
239000000203 mixture Substances 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
230000002411 adverse Effects 0.000 description 7
230000008485 antagonism Effects 0.000 description 7
206010033128 Ovarian cancer Diseases 0.000 description 6
208000037844 advanced solid tumor Diseases 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
231100000371 dose-limiting toxicity Toxicity 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
206010061535 Ovarian neoplasm Diseases 0.000 description 4
206010047700 Vomiting Diseases 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
238000004820 blood count Methods 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
201000010536 head and neck cancer Diseases 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
208000037841 lung tumor Diseases 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
206010065553 Bone marrow failure Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
208000032140 Sleepiness Diseases 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
229940125683 antiemetic agent Drugs 0.000 description 2
239000002111 antiemetic agent Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000034994 death Effects 0.000 description 2
ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000000174 oncolytic effect Effects 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
206010043554 thrombocytopenia Diseases 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010060933 Adverse event Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010015727 Extensor plantar response Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000013038 Hypocalcemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010045170 Tumour lysis syndrome Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
BZRPOJFQTMPGJK-UHFFFAOYSA-N carbamic acid;2-fluoropyrimidine Chemical compound NC(O)=O.FC1=NC=CC=N1 BZRPOJFQTMPGJK-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000000705 hypocalcaemia Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
231100000338 sulforhodamine B assay Toxicity 0.000 description 1
238000003210 sulforhodamine B staining Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
208000010380 tumor lysis syndrome Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000004916 vomit Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

OA1200100078A 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. OA11659A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10180998P	1998-09-25	1998-09-25

Publications (1)

Publication Number	Publication Date
OA11659A true OA11659A (en)	2004-12-08

Family

ID=22286531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100078A OA11659A (en)	1998-09-25	1999-07-08	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Country Status (34)

Country	Link
US (3)	US6469058B1 (de)
EP (1)	EP1115391B1 (de)
JP (1)	JP2002525320A (de)
KR (1)	KR20010075348A (de)
CN (1)	CN1319009A (de)
AP (1)	AP2001002109A0 (de)
AT (1)	ATE225655T1 (de)
AU (1)	AU762079B2 (de)
BG (1)	BG105470A (de)
BR (1)	BR9913952A (de)
CA (1)	CA2342981A1 (de)
CZ (1)	CZ2001905A3 (de)
DE (1)	DE69903458T2 (de)
DK (1)	DK1115391T3 (de)
EA (1)	EA200100369A1 (de)
EE (1)	EE200100187A (de)
ES (1)	ES2185378T3 (de)
GE (1)	GEP20043199B (de)
HK (1)	HK1040190A1 (de)
HR (1)	HRP20010225B1 (de)
HU (1)	HUP0103640A3 (de)
ID (1)	ID30046A (de)
IL (1)	IL141951A0 (de)
IS (1)	IS5888A (de)
NO (1)	NO20011493L (de)
NZ (1)	NZ510504A (de)
OA (1)	OA11659A (de)
PL (1)	PL348673A1 (de)
PT (1)	PT1115391E (de)
SK (1)	SK3602001A3 (de)
TR (1)	TR200100859T2 (de)
WO (1)	WO2000018393A1 (de)
YU (1)	YU22401A (de)
ZA (1)	ZA200102233B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
OA11659A (en) *	1998-09-25	2004-12-08	Warner Lambert Co	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) *	2001-07-02	2003-05-14	Warner-Lambert Company	Kombinační chemoterapie
US7850990B2 (en) *	2001-10-03	2010-12-14	Celator Pharmaceuticals, Inc.	Compositions for delivery of drug combinations
CA2383259A1 (en)	2002-04-23	2003-10-23	Celator Technologies Inc.	Synergistic compositions
US20080075762A1 (en) *	2001-10-03	2008-03-27	Paul Tardi	Compositions for delivery of drug combinations
US20040132825A1 (en) *	2002-03-04	2004-07-08	Bacopoulos Nicholas G.	Methods of treating cancer with HDAC inhibitors
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
AU2003213684C1 (en) *	2002-03-04	2008-10-23	Merck Hdac Research, Llc	Methods of inducing terminal differentiation
CN100566711C (zh) *	2002-04-15	2009-12-09	斯隆-凯特林癌症研究院	治疗癌症的化合物及其用途
US8026216B2 (en)	2002-10-24	2011-09-27	Spectrum Pharmaceuticals, Inc.	Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en)	2002-10-24	2007-02-08	Spectrum Pharmaceuticals, Inc.	Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
AU2003274576A1 (en) *	2002-11-15	2004-06-15	Warner-Lambert Company Llc	Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
RU2240117C1 (ru) *	2003-04-01	2004-11-20	Алтайский государственный медицинский университет	Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (de) *	2003-05-22	2006-04-12	Neopharm, Inc.	Liposomale formulierungen mit einer kombination aus zwei oder mehr wirkstoffen
PE20050206A1 (es) *	2003-05-26	2005-03-26	Schering Ag	Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) *	2004-11-22	2008-11-12	山东蓝金生物工程有限公司	一种抗癌药物组合物
US7957507B2 (en)	2005-02-28	2011-06-07	Cadman Patrick F	Method and apparatus for modulating a radiation beam
CN100443081C (zh) *	2005-04-05	2008-12-17	吴一心	木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en)	2005-05-10	2012-07-31	Tomotherapy Incorporated	System and method of treating a patient with radiation therapy
US8767917B2 (en)	2005-07-22	2014-07-01	Tomotherapy Incorpoated	System and method of delivering radiation therapy to a moving region of interest
EP1907065B1 (de)	2005-07-22	2012-11-07	TomoTherapy, Inc.	Verfahren und system zur anpassung eines strahlentherapiebehandlungsplans auf der grundlage eines biologischen modells
JP2009507524A (ja)	2005-07-22	2009-02-26	トモセラピー・インコーポレーテッド	変形マップに制約を課す方法およびそれを実装するためのシステム
US8229068B2 (en)	2005-07-22	2012-07-24	Tomotherapy Incorporated	System and method of detecting a breathing phase of a patient receiving radiation therapy
US8442287B2 (en)	2005-07-22	2013-05-14	Tomotherapy Incorporated	Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1907064B1 (de)	2005-07-22	2011-06-08	TomoTherapy, Inc.	Verfahren zur bestimmung eines interessierenden bereiches von oberflächenstrukturen mit einem dosiervolumenhistogramm
WO2007014104A2 (en)	2005-07-22	2007-02-01	Tomotherapy Incorporated	System and method of evaluating dose delivered by a radiation therapy system
WO2007014108A2 (en) *	2005-07-22	2007-02-01	Tomotherapy Incorporated	Method and system for evaluating quality assurance criteria in delivery of a treament plan
CN101268474A (zh)	2005-07-22	2008-09-17	断层放疗公司	用于估算实施剂量的方法和系统
EP1970097A3 (de)	2005-07-22	2009-10-21	TomoTherapy, Inc.	Verfahren und System zur Vorhersage der Dosierabgabe
WO2007014093A2 (en)	2005-07-22	2007-02-01	Tomotherapy Incorporated	Method and system for processing data relating to a radiation therapy treatment plan
EP1907057B1 (de)	2005-07-23	2017-01-25	TomoTherapy, Inc.	Vorrichtung zur strahlungstherapiebildgebung und abgabe mttels koordinierter bewegung von gantry und liege
CN101534852B (zh) *	2006-08-31	2013-02-13	光谱医药公司	通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
US8436044B2 (en) *	2008-01-28	2013-05-07	Nanocarrier Co., Ltd.	Pharmaceutical composition or combination drug
FR2937867B1 (fr) *	2008-11-03	2011-03-04	Biorebus	Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
EP2417146B1 (de)	2009-04-06	2016-07-13	Otsuka Pharmaceutical Co., Ltd.	Derives de la (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one pour le traitment du cancer
WO2012003413A1 (en) *	2010-06-30	2012-01-05	The Broad Institute, Inc.	Novel solid forms of tacedinaline
US8691875B2 (en)	2011-07-01	2014-04-08	Broad Institute, Inc.	Solid forms of tacedinaline
US9308235B2 (en)	2012-05-09	2016-04-12	Spectrum Pharmaceuticals, Inc.	Treatment of primary and metastatic carcinoma
EP2711007A1 (de)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	4-Aminopyrazolo[3,4-d]pyrimidine zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brust- und Prostatakrebs
EP2711009A1 (de)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	Verbindungen zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brust- und Prostatakrebs
EP2711008A1 (de)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	N6,N6-dimethyladenosine zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brustkrebs
JP6412020B2 (ja)	2013-02-26	2018-10-24	アキュレイインコーポレイテッド	電磁作動式のマルチリーフコリメーター
US10189797B2 (en) *	2015-12-30	2019-01-29	Duke University	Chemical modulators of immune checkpoints and therapeutic use
WO2020028392A1 (en)	2018-07-30	2020-02-06	Duke University	Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5562925A (en) *	1970-04-20	1996-10-08	Research Corporation Tech. Inc.	Anti-tumor method
NZ219974A (en) *	1986-04-22	1989-08-29	Goedecke Ag	N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) *	1992-12-18	1996-08-29	F. Hoffmann-La Roche Ag	N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (en)	1997-04-24	1998-10-29	Warner-Lambert Company	Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
OA11659A (en) *	1998-09-25	2004-12-08	Warner Lambert Co	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

1999
- 1999-07-08 OA OA1200100078A patent/OA11659A/en unknown
- 1999-07-08 CN CN99811320A patent/CN1319009A/zh active Pending
- 1999-07-08 EP EP99935442A patent/EP1115391B1/de not_active Expired - Lifetime
- 1999-07-08 HK HK02101589.3A patent/HK1040190A1/zh unknown
- 1999-07-08 DK DK99935442T patent/DK1115391T3/da active
- 1999-07-08 PL PL99348673A patent/PL348673A1/xx not_active Application Discontinuation
- 1999-07-08 HU HU0103640A patent/HUP0103640A3/hu unknown
- 1999-07-08 EA EA200100369A patent/EA200100369A1/ru unknown
- 1999-07-08 AU AU50921/99A patent/AU762079B2/en not_active Ceased
- 1999-07-08 AP APAP/P/2001/002109A patent/AP2001002109A0/en unknown
- 1999-07-08 DE DE69903458T patent/DE69903458T2/de not_active Expired - Fee Related
- 1999-07-08 ID IDW20010901A patent/ID30046A/id unknown
- 1999-07-08 BR BR9913952-9A patent/BR9913952A/pt not_active IP Right Cessation
- 1999-07-08 AT AT99935442T patent/ATE225655T1/de not_active IP Right Cessation
- 1999-07-08 HR HR20010225A patent/HRP20010225B1/xx not_active Application Discontinuation
- 1999-07-08 EE EEP200100187A patent/EE200100187A/xx unknown
- 1999-07-08 YU YU22401A patent/YU22401A/sh unknown
- 1999-07-08 NZ NZ510504A patent/NZ510504A/en unknown
- 1999-07-08 TR TR2001/00859T patent/TR200100859T2/xx unknown
- 1999-07-08 CA CA002342981A patent/CA2342981A1/en not_active Abandoned
- 1999-07-08 US US09/744,130 patent/US6469058B1/en not_active Expired - Fee Related
- 1999-07-08 JP JP2000571912A patent/JP2002525320A/ja active Pending
- 1999-07-08 IL IL14195199A patent/IL141951A0/xx unknown
- 1999-07-08 CZ CZ2001905A patent/CZ2001905A3/cs unknown
- 1999-07-08 WO PCT/US1999/015386 patent/WO2000018393A1/en not_active Ceased
- 1999-07-08 KR KR1020017003794A patent/KR20010075348A/ko not_active Withdrawn
- 1999-07-08 PT PT99935442T patent/PT1115391E/pt unknown
- 1999-07-08 ES ES99935442T patent/ES2185378T3/es not_active Expired - Lifetime
- 1999-07-08 GE GEAP19995872A patent/GEP20043199B/en unknown
- 1999-07-08 SK SK360-2001A patent/SK3602001A3/sk unknown
2001
- 2001-03-14 IS IS5888A patent/IS5888A/is unknown
- 2001-03-16 ZA ZA200102233A patent/ZA200102233B/en unknown
- 2001-03-23 NO NO20011493A patent/NO20011493L/no not_active Application Discontinuation
- 2001-04-25 BG BG105470A patent/BG105470A/xx unknown
2002
- 2002-10-08 US US10/184,309 patent/US20030170300A1/en not_active Abandoned
- 2002-10-09 US US10/185,221 patent/US20030086965A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR9913952A (pt)	2001-06-12
US20030086965A1 (en)	2003-05-08
HK1040190A1 (zh)	2002-05-31
HUP0103640A2 (en)	2002-06-29
GEP20043199B (en)	2004-03-25
BG105470A (en)	2001-12-29
EP1115391A1 (de)	2001-07-18
SK3602001A3 (en)	2002-07-02
JP2002525320A (ja)	2002-08-13
PL348673A1 (en)	2002-06-03
AU5092199A (en)	2000-04-17
IS5888A (is)	2001-03-14
DK1115391T3 (da)	2003-02-10
WO2000018393A1 (en)	2000-04-06
CN1319009A (zh)	2001-10-24
YU22401A (sh)	2004-03-12
NZ510504A (en)	2003-09-26
HRP20010225A2 (en)	2002-04-30
DE69903458D1 (de)	2002-11-14
KR20010075348A (ko)	2001-08-09
EP1115391B1 (de)	2002-10-09
DE69903458T2 (de)	2003-07-10
CZ2001905A3 (cs)	2001-08-15
CA2342981A1 (en)	2000-04-06
TR200100859T2 (tr)	2001-08-21
ID30046A (id)	2001-11-01
NO20011493D0 (no)	2001-03-23
ZA200102233B (en)	2002-06-18
NO20011493L (no)	2001-05-23
ATE225655T1 (de)	2002-10-15
ES2185378T3 (es)	2003-04-16
EE200100187A (et)	2002-08-15
HRP20010225B1 (en)	2004-10-31
US20030170300A1 (en)	2003-09-11
HUP0103640A3 (en)	2003-01-28
IL141951A0 (en)	2002-03-10
AU762079B2 (en)	2003-06-19
US6469058B1 (en)	2002-10-22
AP2001002109A0 (en)	2001-03-31
PT1115391E (pt)	2003-02-28
EA200100369A1 (ru)	2001-10-22

Publication	Publication Date	Title
OA11659A (en)	2004-12-08	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CN100411628C (zh)	2008-08-20	空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用
JP2011140521A (ja)	2011-07-21	タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
JP2009536956A (ja)	2009-10-22	抗癌治療法
AU1583201A (en)	2001-06-06	Combination chemotherapy
EP0794784A1 (de)	1997-09-17	Kombinationschemotherapie von suramin mit einem vinca-alkaloid oder estramustine
EP1273296B1 (de)	2003-11-26	Kombination von acetyldinalin und docetaxel
MXPA04006822A (es)	2004-12-08	Combinaciones que comprenden epotilonas y anti-metabolitos.
US20030134893A1 (en)	2003-07-17	Combination chemotherapy
EP1658084A2 (de)	2006-05-24	Zusammensetzungen enthaltend zd6126 zusammen mit 5-fu, cpt-11 oder 5-fu und cpt-11 mit gefässschädigender aktivität und deren verwendung zur behandlung von kolorecktalemkarcinoma
Waud et al.	1992	Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice
TWI307628B (en)	2009-03-21	Use of zd0473 in combination with a non-platinum based anti-cancer agent
US20060058260A1 (en)	2006-03-16	Combination therapy with gemcitabine and zd6126